Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ehsan Abdeshahian

Physical Medicine & Rehabilitation New York, NY Medical Doctor

NPI 1871844720 CMS profile 357806

67 Wall St Apt 10F, New York, NY 10005

Open in the dashboard

General payments

$12,222

404 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ehsan Abdeshahian of New York, NY is reported in the CMS Open Payments database as having received $12,222 across 404 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,541 53
2024 General $2,548 118
2023 General $1,189 31
2022 General $375 13
2021 General $1,112 22
2020 General $1,194 43
2019 General $4,264 124

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ehsan Abdeshahian
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Ehsan Abdeshahian were reported at $1,541. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Ehsan Abdeshahian Physical Medicine & Rehabilitation median Middle half National median
2019 $4,264 $133 $45–$390 $163
2020 $1,194 $88 $29–$272 $114
2021 $1,112 $116 $33–$360 $132
2022 $375 $123 $40–$378 $149
2023 $1,189 $131 $43–$396 $160
2024 $2,548 $141 $45–$409 $164
2025 $1,541 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $4,543 44 payments
  2. Boston Scientific Corporation $1,392 62 payments
  3. Abbott Laboratories $1,175 51 payments
  4. Medtronic, Inc. $712 30 payments
  5. Zyla Life Sciences $685 72 payments
  6. Indivior Inc. $523 35 payments
  7. Merz North America, Inc. $493 5 payments
  8. Vertos Medical, Inc. $381 4 payments
  9. Collegium Pharmaceutical, Inc. $316 19 payments
  10. Scilex Pharmaceuticals Inc. $245 13 payments
  11. Other $1,756 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,303 396 payments
  2. Travel and Lodging $1,915 7 payments
  3. Education $4 1 payment
Products named General payments · program years 2019–2025
  1. Senza Spinal Cord Stimulation System $3,046 20 payments
  2. WaveWriter Alpha Prime 16 $1,231 53 payments
  3. Omnia $976 12 payments
  4. SPRIX $681 71 payments
  5. SUBLOCADE $484 33 payments
  6. INTELLIS ADAPTIVESTIM $465 19 payments
  7. Xeomin $447 3 payments
  8. mild Device Kit $381 4 payments
  9. Senza $321 9 payments
  10. XTAMPZA $301 18 payments
  11. Other $4,081 165 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

186

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$2,292

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

67.2%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 55 $897
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 26 $442
Oxycodone Hcl Generic 24 $370
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 14 $158
Acetaminophen-Codeine Acetaminophen With Codeine Brand 18 $155
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 12 $147
Tramadol Hcl Generic 37 $122

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$604,643

Of which drugs: $7,158

Medicare patients

1,431

Average age 68

Services billed

9,475

905 women, 526 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 38%
Depression 35%
Ischemic heart disease 25%
Chronic kidney disease 24%
COPD 23%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 27 291 $24

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SUBLOCADE
  • Indivior Inc. $260
$260 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $60
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

404 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record